Is Truforma FDA approved? In April 2020, Zomedica announced that they had completed platform verification of TRUFORMA, which confirms the achievement of instrument design specifications, and follows FDA Medical Device design control guidelines to ensure the product was built correctly.
What is Zomedica new product?
Zomedica's Pet Lab Product Launch Will Push Its Value Higher. Zomedica (NYSEAMERICAN:ZOM) made a decision last week to launch Truforma, its pet lab diagnostic system, early. That launch brings in its first revenue and will help propel its commercialization efforts.
How accurate is Truforma?
Truforma achieved statistically significant high correlation of R greater than 0.95 to the Siemens Immulite Canine tT4 assay (P value less than 0.0001). Dynamic range is the functional range of a test over which the concentrations of an analyte can be measured with acceptable accuracy and precision.
What does the company Zomedica do?
Zomedica Corp. operates as a veterinary health company, which engages in the discovery, development, and commercialization of pharmaceuticals for the companion pet. It offers products for dogs and cats by focusing on the unmet needs of clinical veterinarians.
What does Truforma cost?
No one wants to be the first to try an untested device, let alone one that costs $8,750 with just a few tests available. Zomedica has also made some mistakes along the way. The biggest pitfall may have been getting Tiger King star Carole Baskin to issue a video endorsement early this year.
Related investments for Is Truforma FDA Approved?
Does Zomedica own Truforma?
Zomedica Announces First Commercial Sale of Its Truforma® Platform. (NYSE American: ZOM) (“Zomedica” or the “Company”), a veterinary health company creating point-of-care diagnostics products for dogs and cats, yesterday recorded the first veterinarian sale of TRUFORMA® and officially entered commercialization.
What can Truforma do?
TRUFORMA is an innovative, non-optical, fluorescence-free platform that delivers accurate, reliable results when assessing complex conditions and discriminating between healthy and diseased patients.
Who bought Truforma?
Zomedica Corp., a veterinary health company creating point-of-care diagnostics products for dogs and cats, yesterday recorded the first veterinarian sale of TRUFORMA® and officially entered commercialization.
Is Truforma released?
Truforma is a toaster-sized device that runs assays to detect thyroid and adrenal disease in dogs and cats. Zomedica plans to sell the platform and assays to veterinarians for in-office use. The company will release Truforma along with three assays in a limited geographic area as of March 30.
Does Zomedica have FDA approval?
Zomedica Opens First Investigational New Animal Drug Application with FDA Center for Veterinary Medicine. ANN ARBOR, Mich., May 10, 2016 (GLOBE NEWSWIRE) -- Zomedica Pharmaceuticals Corp.
Who is Zomedica partnered with?
Detroit's Seraph Biosciences and Ann Arbor's Zomedica Partner to Create a Diagnostic Device for Veterinarians. Seraph Biosciences Inc. in Detroit has entered into a development, commercialization, and exclusive distribution agreement with Ann Arbor's Zomedica Pharmaceuticals Corp., Zomedica announced Thursday.
Why is Zomedica dropping?
CEO Robert Cohen said the move was precipitated by "changes at our current distributor that we believe have impacted its ability to market our products effectively." Those words likely startled investors, many of whom decided to sell their shares. Zomedica's stock price dropped sharply on Thursday.
Is Zomedica real?
Zomedica Corp. operates as a veterinary biopharmaceutical company. The Company focuses on the needs of the veterinarians by offering drug discovery and development for pet health.
Is Zomedica a pump and dump?
Zomedica Pharmaceuticals (NYSEMKT:ZOM) stock is the latest pump-and-dump looking to take investors for a ride.
Is Truforma a game changer?
The game-changer here is that Truforma enables veterinarians to analyze serum samples at their clinics in less than 15 minutes, saving them the trouble of sending assays to the laboratory. Its device doesn't only work well in theory.
Will Zom recover?
ZOM stock will likely struggle to recover in price over the next few months. It's going to be awhile before this early stage company will again have the chance to prove itself to investors. Having said that, investors with a high appetite for risk, and a willingness to go against the grain, may want to buy today.
Is Zomedica a long term investment?
At one point this year, Zomedica Pharmaceuticals (NYSEAMERICAN:ZOM) stock had soared a whopping 1,000%. However, it has fallen meaningfully in the past three months. Currently, the shares are working their way back up again.
How do I buy Zomedica stock?
Does Zomedica have competitors?
Zomedica Pharmaceuticals's top competitors include Quark Pharmaceuticals, Patterson Veterinary Supply, Lintjeshof and KM Biologics.
What will Zom be in March?
(NYSE American: ZOM) (“Zomedica” or the “Company”), a veterinary health company creating point-of-care diagnostics products for dogs and cats, today announced that it expects to begin commercialization of its TRUFORMA™ point-of-care diagnostic platform on March 30, 2021.
What can I expect from Zomedica?
The 1 analysts offering 12-month price forecasts for Zomedica Corp have a median target of 1.20, with a high estimate of 1.20 and a low estimate of 1.20. The median estimate represents a +218.73% increase from the last price of 0.38.
Will NAKD stock recover?
NAKD stock became a hit with the Reddit trading crowd and has done well to fortify its balance sheet. It's now debt-free and has evolved into a pure-play e-commerce business. Unfortunately, there are several loopholes in its turnaround strategy, so it is unlikely things will change significantly for the company.
When did SNDL go public?
Sundial (SNDL) went public on the Nasdaq stock market on Aug 1, 2019 at US$13.00 per share.